18 results about "Aqueous humor outflow" patented technology

A method and device for reducing intraocular pressure in a patient. The method may comprise administering a viscoelastic material in Schlemm's canal to open aqueous humor outflow pathways. The device is adapted to perform the method. The viscoelastic material may be configured to lower the intraocular pressure within the eye.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The invention provides a gRNA, an AAV expression vector and a CRISPR-CasRx system for treating glaucoma, and particularly provides (a) a gene editing protein or an expression vector thereof, the gene editing protein comprises a VI type Cas protein; and (b) gRNA or an expression vector thereof, the gRNA is RNA for guiding the gene editing protein to be specifically combined with an aqueous humor outflow related gene and / or an aqueous humor generation related gene in an eye tissue, the aqueous humor outflow related gene comprises Rock1 and Rock2, and the aqueous humor generation related gene comprises Aqp1 and Adrb2. The gRNA designed aiming at exon regions of aqueous fluid outflow related genes (such as Rock1 and Rock2) and aqueous fluid generation related genes (such as Aqp1 and Adrb2) has the characteristics of relatively high editing efficiency and relatively low off-target rate, and the combination of the VI type Cas protein and the gRNA designed by the invention can effectively prevent and / or treat glaucoma or ocular hypertension.

A method and device for reducing intraocular pressure in a patient. The method may comprise administering a viscoelastic material in Schlemm's canal to open aqueous humor outflow pathways. The device is adapted to perform the method. The viscoelastic material may be configured to lower the intraocular pressure within the eye.

The application discloses a teaching simulative human eyeball aqueous humor circulation model in the technical field of eyeball aqueous humor circulation models, which comprises a model box, an eyeball model assembly arranged in the model box, a functional body arranged at the top of the model box and a pump assembly arranged in the functional body. The eyeball model assembly comprises an eyeball wall, an eyeball and an optic nerve, and the eyeball wall is provided with a cornea at the front end. An iris is arranged on the side of the cornea close to the eyeball, the space between the cornea and the iris is an anterior chamber, the included angle between the cornea and the iris is an anterior chamber angle, the center of the iris is provided with a pupil, the iris is provided with a lens on the side close to the eyeball, the lens is provided with a zonular ligament around the lens, and the other end of the zonular ligament is fixedly connected with a ciliary body. The space between the iris and the lens constitutes a posterior chamber. The application has the advantages of simple structure, simulation of the process that the aqueous humor is retained in the eye to press the optic nerve when the anterior chamber angle is closed or the aqueous humor outflow passage is blocked, and convenience for medical students to understand the process that the optic nerve is pressed by the increased intraocular pressure when the aqueous humor passage is blocked.

An aqueous humor outflow device comprises an arcuate scaffold that extends continuously in a circumferential direction from a first end to a second end of the aqueous humor outflow device and has a cross-sectional area that allows the arcuate scaffold to fit within a conventional aqueous humor outflow pathway of a mammalian eye. The arcuate scaffold comprises a docking station or a port within which to retain an implant device, such as a drug eluting device or a drug delivery device.

The invention provides a scleroscope device for noninvasive monitoring of an aqueous humor outflow coefficient, a monitoring method and a system, relates to the technical field of medical monitoring equipment for the ophthalmology department, and solves the problems that an aqueous humor outflow coefficient measuring method in the prior art is high in invasiveness, incapable of achieving continuous monitoring, insufficient in precision and poor in data synchronism. The sclera lens device comprises a sclera lens, the sclera lens comprises a central area, an edge landing area and a transition area connecting the central area and the edge landing area, and the edge landing area is used for making contact with the sclera of a user and providing support for the transition area and the central area; the phased array transducer matrix comprises a plurality of transducers which are annularly distributed in the transition area; the dynamic deflection control module is arranged in the transition area and is electrically connected with each transducer so as to control the excitation time delay of each transducer; the intraocular pressure monitoring module is arranged in the central area; and the signal processing module is arranged in the transition area.

A method for treating advanced primary angle closure glaucoma (PACG) includes steps of: S1, utilizing surgical peripheral iridectomy (SPI) to eliminate pupillary block; S2, utilizing goinosynchialysis (GSL) to separate peripheral anterior synechia (PAS) in the anterior chamber angle with the assistance of a gonioscope and a chopper; and S3, utilizing goniotomy (GT) to incise a dysfunctional trabecular meshwork and a Schlemm canal, so as to remove a dysfunctional trabecular meshwork, enhance outflow of aqueous humor, and reduce intraocular pressure.

Laser-based ophthalmic systems and methods can be used to treat glaucoma and other conditions of the eye. The laser system can be used to form openings or partial-thickness channels in the trabecular meshwork to promote aqueous humor outflow. Scanning approaches provided herein can create either fully perforating “full hole” ablations or partial-disruption “soft holes.”

The implant device for eye diseases is for insertion into the eyeball. It includes a tube configured such that one end is inserted into the anterior chamber of the eyeball and having a hollow formed for the drainage of aqueous humor; and a matrix member made of a material capable of impregnating and releasing a drug and coupled to the outer surface of the tube. At this time, at least a part of the matrix member can have a cross-section larger than the diameter of the tube. When using the implant device for eye diseases, anti-fibrotic agents such as dexamethasone, mitomycin-C (MMC), 5-fluorouracil (5-FU), triamcinolone (TA), anti-vascular endothelial growth factor (anti-VEGF) drugs, and transforming growth factor-beta inhibitor (TGF-beta inhibitor) are loaded onto the matrix member so that the anti-fibrotic agent is released from the matrix member to the surrounding tissue after the insertion of the implant device, thereby preventing the drainage outlet of the tube from being blocked by fibrosis.

Disclosed herein are devices, systems, and methods configured to safely regulate aqueous outflow in a patient's eye while dynamically maintaining the normal range of intraocular pressure. An exemplary membrane implant includes a plurality of topographical features implemented on first and second surfaces of the implant. The topographical features include an interconnected channel network configured to direct aqueous in the patient's eye to flow through and across the surfaces of the membrane implant to reduce intraocular pressure. A plurality of control structures are implemented on one or more selected locations of the first and second surfaces to regulate the aqueous in the patient's eye.

The present disclosure relates to a drug for preventing and / or treating glaucoma. Specifically, provided in the present disclosure is the use of an adenosine A2A receptor antagonist in the treatment and prevention of glaucoma. The treatment and prevention include, but are not limited to, inhibiting aqueous humor production in non-pigmented epithelial cells of the ciliary body, reducing elevated intraocular pressure caused by the obstruction of aqueous humor outflow due to fibrosis and thickening of the trabecular meshwork, improving the fluidity of aqueous humor in the eye, inhibiting pathological changes in the trabecular meshwork, and achieving a protective effect on retinal cells. Additionally, the drug of the present disclosure may also help to reduce the problem of drug tolerance in the treatment of glaucoma, can lower intraocular pressure in glaucoma patients and provide a protective effect on optic nerves, and provides a more effective strategy for long-term treatment.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

The present application provides a kind of outflow facility of aqueous humor non-invasive monitoring scleral mirror device, monitoring method and system, it is related to ophthalmic medical monitoring equipment technical field, solve the problems of strong invasiveness, cannot continuous monitoring, insufficient precision and poor data synchronism of the existing technology in aqueous humor outflow coefficient measurement method;Wherein the scleral mirror device includes: scleral mirror, scleral mirror includes center area, edge landing area and the transition zone connecting center area and edge landing area, edge landing area is used to contact the sclera of user and provide support to transition zone and center area;Phased array transducer matrix, phased array transducer matrix includes multiple ring-shaped distribution in transition zone transducer;Dynamic deflection control module, dynamic deflection control module is set in transition zone, and is electrically connected with each transducer, to control the excitation time delay of each transducer;Intraocular pressure monitoring module, intraocular pressure monitoring module is set in center area;Signal processing module, signal processing module is set in transition zone.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

The invention discloses an artificial filtering bubble and a glaucoma drainage device with the artificial filtering bubble. The artificial filtering bubble can be switched between fluid resistances or control the flowing-out speed of aqueous humor, and the pressure control function of the artificial filtering bubble is irrelevant to the condition of subconjunctival tissue. The artificial filtering bubble comprises a filtering bubble body, the filtering bubble body is formed by laminating two layers of biomaterial films; the peripheries of the two layers of biological material films are fixed by thermal bonding; the biological material is a biomedical elastomer containing a hydrophilic group; a plurality of micropores are formed in each of the upper and lower layers of biomaterial membranes of the filtering bubble body; a drainage structure for introducing liquid is arranged on the filtering bubble body. By adopting the artificial filtering bubble and the glaucoma drainage apparatus with the artificial filtering bubble, self-regulation of pressure control can be realized; controlling and maintaining IOP within a range of health values; meanwhile, the surgical success rate can be increased, the functional difference of filtering bubbles among different patients can be isolated, and complications such as hypoocular pressure can be avoided.

The invention provides an intraocular pressure regulation and control system based on an ultrasonic technology, a positioning module is deployed on the outer side of a target human eyelid and used for positioning a pupil center point of a human eyeball in a first posture, and a measurement module is deployed on the outer side of the target human eyelid and used for measuring the real-time resonant frequency of the human eyeball in the first posture. The ultrasonic module is deployed on the outer side of a target human eyelid, a plurality of array elements of the ultrasonic module are arranged opposite to a human eye trabecular meshwork tissue coverage area, and the ultrasonic module is used for applying ultrasonic energy matched with the human eyeball real-time intraocular pressure parameter to the human eye trabecular meshwork tissue, so that a human eye aqueous humor outflow channel is dredged, and the human eye intraocular pressure parameter is calculated in real time. And human intraocular pressure parameters are adjusted. According to the invention, the intraocular pressure regulation and control system is not in direct contact with the human eyeball tissue, the intraocular pressure parameter is indirectly measured and obtained through the vibration frequency of the human eyeball, and the function of accurately and individually regulating the intraocular pressure of the human body is met by applying ultrasonic energy to the human eye trabecular meshwork tissue.

A bioengineered endothelial stent designed for implantation in Schlemm's canal enhances aqueous humor outflow and restores physiological intraocular pressure regulation. Unlike conventional devices, this stent integrates transplanted Schlemm's canal endothelial cells (SCECs) to restore mechanosensitive outflow regulation. The stent features a biocompatible or biodegradable scaffold with an endothelial cell-seeding system to support integration into the Schlemm's canal inner wall. This regenerative approach maintains physiological resistance and prevents excessive drainage, offering a stable, cell-based alternative to conventional glaucoma stents.